Novo Nordisk and Oxford University team up to develop novel treatments for rheumatoid arthritis
24 April 2012 | By Novo Nordisk
Novo Nordisk and the Oxford University announce a new partnership...
List view / Grid view
24 April 2012 | By Novo Nordisk
Novo Nordisk and the Oxford University announce a new partnership...
23 April 2012 | By Novo Nordisk
Two studies show a significant reduction in the rates of nocturnal hypoglycaemia by 25%, compared to insulin glargine...
17 April 2012 | By Novo Nordisk
Novo Nordisk broke ground on a new USD 100 million plant that will formulate and fill modern insulin into Novo Nordisk’s Penfill® cartridges...
24 January 2012 | By Novo Nordisk
Novo Nordisk announced that the company will establish a type 1 diabetes R&D center in Seattle, US...
6 December 2011 | By Novo Nordisk
Insulin degludec / insulin aspart reduced rates of hypoglycaemia by 58%...
5 December 2011 | By Novo Nordisk
New data from the A1chieve® study...
14 November 2011 | By Novo Nordisk
On World Diabetes Day, new numbers on the prevalence of diabetes have been released by the IDF...
10 October 2011 | By Novo Nordisk
Victoza® (liraglutide injection), is now commercially available in China...
23 September 2011 | By Novo Nordisk
CHMP has adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir®...
23 September 2011 | By Novo Nordisk
CHMP has adopted a positive opinion on the extended use of Novo Nordisk’s basal insulin analogue, insulin detemir...
13 September 2011 | By Novo Nordisk
Patient satisfaction when switching from sitagliptin to Victoza®...
25 August 2011 | By Novo Nordisk
Novo Nordisk is investing around 1 billion Danish kroner (134 million euros) in two new office buildings with surrounding green space in Bagsværd, Denmark...
27 July 2011 | By Novo Nordisk
Ultra-long-acting insulin degludec, lowers blood glucose levels...
14 July 2011 | By Novo Nordisk
Novo Nordisk has been granted approval by the European Commission for the new prefilled insulin pen – FlexTouch®...
27 June 2011 | By Novo Nordisk
Ultra-long-acting insulin degludec, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar)...